Skip to content

Ernexa Therapeutics Inc.: net property, plant and equipment

Ernexa Therapeutics net property, plant and equipment: $94.0 thousand at 2025-12-31, up 10.6% on the year. 16 values since 2010, each linked to its SEC filing.

All Ernexa Therapeutics Inc. financial histories

At a glance

Ernexa Therapeutics reported net property, plant and equipment of $94.0 thousand at 2025-12-31, up 10.6% from $85.0 thousand a year earlier. From 2010 to 2025 it fell at a compound 21.6% a year, from $3.64 million to $94.0 thousand. Across the last five reported years it ranged from $85.0 thousand (2024-12-31) to $670.0 thousand (2021-12-31). That was 1.6% of total assets ($5.83 million) at the same date.

Computed from the values in the table below, in USD; each links to the filing it came from.

What this measure means

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2010-12-31 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Net property, plant and equipment in original reported units, latest-filed observation per period
Period startPeriod endValueUnitFiledSource filing
-2025-12-3194,000USD2026-03-1310-K · 0001493152-26-010102 SEC
-2024-12-3185,000USD2026-03-1310-K · 0001493152-26-010102 SEC
-2023-12-31493,000USD2025-03-1210-K · 0001493152-25-010051 SEC
-2022-12-31236,000USD2024-03-1410-K · 0001140361-24-013254 SEC
-2021-12-31670,000USD2023-03-2010-K · 0001140361-23-012418 SEC
-2020-12-31594,000USD2022-07-0110-K/A · 0001140361-22-024668 SEC
-2019-12-312,822,000USD2021-03-1110-K · 0001493152-21-005827 SEC
-2018-12-314,667,000USD2020-03-1910-K · 0001493152-20-004343 SEC
-2017-12-313,678,000USD2019-03-2210-K · 0001493152-19-003770 SEC
-2016-12-313,101,000USD2018-03-0910-K · 0001493152-18-003164 SEC
-2015-12-313,915,000USD2017-03-0910-K · 0001493152-17-002280 SEC
-2014-12-313,400,000USD2016-03-1510-K · 0001493152-16-008049 SEC
-2013-12-313,237,000USD2015-03-2710-K · 0001019687-15-001115 SEC
-2012-12-313,783,000USD2014-03-3110-K · 0001019687-14-001135 SEC
-2011-12-314,255,000USD2013-03-2910-K · 0001019687-13-001065 SEC
-2010-12-313,638,000USD2012-03-3010-K · 0001019687-12-001146 SEC

Related Ernexa Therapeutics Inc. histories

All 64 Ernexa Therapeutics histories

Inspect the source

Entity
Ernexa Therapeutics Inc. / CIK 0000748592
Captured
SEC response SHA-256
c12754d65dfa742127976ccd7c75bc4379d46dc7b617393cfbda0b7763329d5c

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

The MCP server is free and MIT-licensed: npx -y canli-mcp. If these records help your research, a star on GitHub helps other researchers find them.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000748592.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))